AbCellera Biologics
ABCL
130 hedge funds and large institutions have $1.1B invested in AbCellera Biologics in 2022 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 41 increasing their positions, 37 reducing their positions, and 21 closing their positions.
238% more call options, than puts
Call options by funds: $27.1M | Put options by funds: $8.04M
33% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 21
11% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 37
5% more funds holding
Funds holding: 124 → 130 (+6)
0% more funds holding in top 10
Funds holding in top 10: 9 → 9 (0)
0.71% less ownership
Funds ownership: 40.68% → 39.97% (-0.71%)
32% less capital invested
Capital invested by funds: $1.63B → $1.1B (-$524M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$70.8M |
| 2 |
Lazard Asset Management
New York
|
+$27.4M |
| 3 |
Renaissance Technologies
New York
|
+$19.7M |
| 4 |
Millennium Management
New York
|
+$7.55M |
| 5 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$5.95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$52.1M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$35.8M |
| 3 |
Swedbank
Stockholm,
Sweden
|
-$28M |
| 4 |
SM
SB Management
Abu Dhabi,
United Arab Emirates
|
-$19.4M |
| 5 |
CII
Capital International Inc
Los Angeles,
California
|
-$13.3M |
ABCL Hedge Fund Activity: Q1 2022 in Review
130 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in AbCellera Biologics (ABCL) for Q1 2022, worth a combined $1.1B — down 32% from $1.63B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new ABCL positions and 21 closed out — a net gain of 7 holders — while 41 added to existing stakes and 37 trimmed.
The largest buyer was Baillie Gifford & Co, adding an estimated $70.8M. The largest seller was Capital International Investors, cutting an estimated $52.1M.
- 130 institutional investors held AbCellera Biologics (ABCL) as of Q1 2022, up from 124 in Q4 2021.
- Funds reported $1.1B of AbCellera Biologics stock for Q1 2022, down 32% quarter-over-quarter.
- 28 funds opened new AbCellera Biologics positions in Q1 2022 and 21 closed out, a net change of +7 holders.
- The largest AbCellera Biologics buyer in Q1 2022 was Baillie Gifford & Co, an estimated $70.8M added.
- The largest AbCellera Biologics seller in Q1 2022 was Capital International Investors, an estimated $52.1M sold.
Based on aggregated 13F filings for Q1 2022.